Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report

被引：0
作者：
Li, Shuluan [1 ,2 ]
Zhang, Pei [3 ]
Wang, Tianyu [2 ,4 ]
Wang, Jie [3 ]
Duan, Jianchun [3 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Dept Med Oncol Natl,Canc Ctr, Shenzhen 100021, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Dept Med Oncol,Natl Canc Ctr, Beijing 100021, Peoples R China
[4] Chinese Acad Med Sci & Peking Union Med Coll, Dept Breast Surg, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Shenzhen, Peoples R China
来源：
THORACIC CANCER | 2021年 / 12卷 / 23期
关键词：
ALK; brigatinib; chemotherapy; lung squamous cell carcinoma; 1ST-LINE CRIZOTINIB; OPEN-LABEL; CANCER; ROS1;
D O I：
10.1111/1759-7714.14133
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The definitive efficacy of anaplastic lymphoma kinase (ALK) inhibitors in ALK positive lung squamous cell carcinoma (sqCC) patients remain unclear. Here, we report a case in which brigatinib had a therapeutic effect on ALK-positive lung squamous cell carcinoma. The patient in this report was diagnosed with ALK-positive lung squamous cell carcinoma with brain metastases, and received brigatinib after failure of first-line chemotherapy. Response duration was approximately 11 months, with tolerable side effects. In conclusion, a good clinical effect was achieved in a patient with ALK positive lung squamous cell carcinoma who received treatment with an ALK inhibitor.
引用
收藏
页码：3273 / 3276
页数：4
相关论文
共 50 条
  • [41] Pulmonary artery pseudoaneurysm-induced massive hemoptysis after chemotherapy combined with tislelizumab for lung squamous cell carcinoma: a case report
    Yang, Xue-Jiao
    Wu, Yong-Juan
    Wang, Jing-Zhong
    Zheng, Yu-Lan
    Li, Xiao-Qi
    FRONTIERS IN MEDICINE, 2025, 12
  • [42] Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)
    Descourt, Renaud
    Perol, Maurice
    Rousseau-Bussac, Gaelle
    Planchard, David
    Mennecier, Bertrand
    Wislez, Marie
    Cortot, Alexis
    Guisier, Florian
    Galland, Loick
    Do, Pascal
    Schott, Roland
    Dansin, Eric
    Arrondeau, Jennifer
    Auliac, Jean-Bernard
    Chouaid, Christos
    LUNG CANCER, 2019, 136 : 109 - 114
  • [43] Case Report: EGFR-Positive Early-Stage Lung Adenocarcinoma Transforming to Squamous Cell Carcinoma After TKI Treatment
    Liao, Jiatao
    Li, Yuan
    Liu, Chang
    Long, Qianqian
    Wang, Jialei
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [44] Multiline treatment of advanced squamous cell carcinoma of the lung: A case report and review of the literature
    Yang, Xin
    Peng, Ping
    Zhang, Li
    WORLD JOURNAL OF CLINICAL CASES, 2019, 7 (14) : 1899 - 1907
  • [45] ALK and ROS1 Double-Rearranged Lung Squamous Cell Carcinoma Responding to Crizotinib Treatment: A Case Report
    Li, Qiong
    Wu, Jian
    Yan, Li-Xu
    Huang, Jun-Wei
    Zhang, Zhou
    Zhang, Jin-E
    Gao, Xing-Lin
    Luo, Ze-Ru
    Liu, Jing
    Yang, Shi-Fang
    Liu, Yan-Hui
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (12) : E193 - E197
  • [46] Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
    Lewis, Whitney E.
    Hong, Lingzhi
    Mott, Frank E.
    Simon, George
    Wu, Carol C.
    Rinsurongkawong, Waree
    Lee, J. Jack
    Lam, Vincent K.
    Heymach, John V.
    Zhang, Jianjun
    Le, Xiuning
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (11):
  • [47] Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report
    Wiedemann, Christiane
    Kazdal, Daniel
    Cvetkovic, Jelena
    Kunz, Julia
    Fisch, David
    Kirchner, Martina
    Kriegsmann, Mark
    Sueltmann, Holger
    Heussel, Claus-Peter
    Bischoff, Helge
    Thomas, Michael
    Stenzinger, Albrecht
    Christopoulos, Petros
    COLD SPRING HARBOR MOLECULAR CASE STUDIES, 2022, 8 (06):
  • [48] Case Report: Opportunities and Challenges of Immunotherapy in Heavily-Treated EGFR-Mutant Advanced Squamous Cell Lung Carcinoma After Progression on EGFR-TKIs and Chemotherapy
    Jin, Wei
    Wang, Xin
    Wang, Jie
    Lin, Lin
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [49] Cetuximab combined with chemotherapy for simultaneous esophageal squamous cell carcinoma and colon adenocarcinoma: A case report
    Luo, Xin-Xin
    Du, Yu-Xuan
    Zhang, Qi-Qing
    Zhang, Lin
    Zeng, Shu-Ying
    Yu, Zhi-Hong
    Shen, Peng
    Feng, Zheng-Quan
    WORLD JOURNAL OF CLINICAL CASES, 2024, 12 (15)
  • [50] A Case Report of Nephrotic Syndrome Associated with Squamous Cell Carcinoma of the Lung
    Fujita, Yoshitsugu
    Eguchi, Kenji
    Seki, Nobuhiko
    Miyazawa, Teruomi
    Inoue, Ken
    INTERNATIONAL MEDICAL JOURNAL, 2009, 16 (01): : 57 - 58
12345